Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
July 10 2023 - 10:26AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of July 2023
Commission file number: 001-32749
FRESENIUS
MEDICAL CARE AG & Co. KGaA
(Translation of registrant's name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X x Form 40-F
¨
This Form 6-K, including all exhibits hereto, is hereby incorporated
by reference into the registration statement on Form F-4 filed by the registrant under the Securities Act of 1933, Registration No. 333-271081,
which was declared effective by the SEC on June 6, 2023.
EXHIBITS
The following exhibits are being furnished with
this Report:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
DATE: July 10, 2023
|
|
Fresenius
Medical Care AG & Co. KGaA, |
|
|
a
partnership limited by shares, represented by: |
|
|
|
|
|
fresenius
medical care management ag, its |
|
|
General
Partner |
|
By: |
/s/ Helen Giza |
|
Name: |
Helen Giza |
|
Title: |
Chief Executive Officer, Chair of the Management Board of the General Partner and Acting Chief Financial Officer |
|
|
|
|
By: |
/s/ Dr. Katarzyna Mazur-Hofsäß |
|
Name: |
Dr. Katarzyna Mazur-Hofsäß |
|
Title: |
CEO Care Enablement and member of the Management Board of the General Partner |
Exhibit 99.1
Press Release |
Media
Contact |
|
Steffen
Rinas |
|
T
+49 6172 608-6698 |
|
steffen.rinas@fresenius.com |
|
|
|
Contact
for analysts and investors |
|
Dr. Dominik
Heger |
|
T
+49 6172 609-2601 |
|
dominik.heger@fmc-ag.com |
|
|
|
www.freseniusmedicalcare.com |
Under
the U.S. Securities Act of 1933, as amended (the “Securities Act”), this press release may be deemed to be offering material
of Fresenius Medical Care AG & Co. KGaA (“FME”). FME has filed a registration statement on Form F-4 under the
Securities Act with the U.S. Securities and Exchange Commission (the “SEC”), including an information statement/prospectus
constituting a part thereof. FME SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED
OR THAT WILL BE FILED WITH THE SEC, INCLUDING THE INFORMATION STATEMENT/PROSPECTUS THAT IS PART OF THE REGISTRATION STATEMENT,
AS THEY BECOME AVAILABLE, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED CONVERSION DESCRIBED THEREIN. The
final information statement/prospectus has been distributed to FME shareholders. Shareholders may obtain a free copy of the disclosure
documents and other documents filed by FME with the SEC at the SEC’s website at www.sec.gov or from Fresenius Medical Care AG &
Co. KGaA, Attention: Investor Relations, Else-Kröner-Straße 1, 61352 Bad Homburg v.d.H., Germany.
July 10, 2023
Fresenius Medical Care appoints Martin Fischer as Chief Financial
Officer
Fresenius Medical Care, the world's leading provider of products and
services for individuals with renal diseases has appointed Martin Fischer (46) as Chief Financial Officer as of October 1, 2023.
He will succeed Helen Giza who was appointed as Chief Executive Officer and Chair of the Management Board in December 2022 and continues
to serve as acting Chief Financial Officer, until her successor will join. Martin Fischer will be based in Bad Homburg, Germany and will
assume responsibility for the Global Finance Organization of Fresenius Medical Care. Upon effectiveness of the Company’s proposed
change of form from KGaA to German stock corporation, Martin Fischer will become a member of the Management Board of Fresenius Medical
Care AG.
Martin Fischer has been Head of Finance for Siemens Healthineers Diagnostics
Division based in Tarrytown, NY, U.S. since 2019. Previously, he headed the Board Office and Organizations function for Siemens Healthineers
after leading the business plan and operating model development for the company’s initial public offering in March 2018. Prior
to that, Fischer held a number of key international operational and finance positions in healthcare within Siemens AG. Martin Fischer
holds a degree in business informatics from the Reutlingen University of Applied Sciences and an MBA from Friedrich Alexander University
in Nuremberg. He completed the Chief Financial Officer Program at Columbia Business School in New York, USA.
Michael Sen, Chairman of the Supervisory Board of Fresenius Medical
Care Management AG, says: "With Martin Fischer's appointment, we are strengthening a vital function in the Management Board of Fresenius
Medical Care. Martin Fischer has a deep understanding of the international healthcare market, both from the U.S. perspective and out of
Germany. That's a decisive advantage in getting the company back on track."
Helen Giza, CEO and Chair of the Management Board, said: "Martin
Fischer has proven that he can successfully drive fundamental change in organizations. In our organizational transformation and turnaround
management, we will benefit from his finance and healthcare expertise. Martin will be an important contributor to the execution of our
strategy in unlocking value as the leading kidney care company."
Martin Fischer said: “There are great challenges ahead of us.
I am convinced of the company's potential and look forward to realizing it together with the global team of Fresenius Medical Care. I
am excited to bring my experience and expertise to support the company’s transformation.”
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment.
Through its network of 4,060 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 343,000 patients
around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius
Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to
various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals,
impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation
or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical
Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Jul 2023 to Jul 2024